| US FDA approves revised SPA for Argos Therapeutics' phase III study of AGS ... - pharmabiz.com |
|
|
pharmabiz.com Biopharmaceutical company Argos Therapeutics Inc. has received the US Food & Drug Administration (FDA) approval of revised Special Protocol Assessment (SPA) for its phase III clinical study of AGS-003 for the treatment of metastatic renal cell |